By MarketNewsVideo Fastenal (FAST) had its estimates reduced UBS (UBS) due to a cautious outlook coupled with weaker than expected first quarter sales.
From: http://www.forbes.com/sites/marketnewsvideo/2013/04/16/analyst-moves-fast-kog/
Tag Archives: FAST
Daily Dividends Report: FAST, ADTN, GLAD, BK, IEX
By MarketNewsVideo Fastenal Company (FAST) announced its quarterly dividend of 20 cents per share, an increase of about 100% over its prior dividend in January of 10 cents. The dividend will be paid on May 30, 2013 to shareholders of record at the close of business on May 2, 2013.
Source: FULL ARTICLE at Forbes Markets
Mobisante Launches Tablet Ultrasound System
By Business Wirevia The Motley Fool
Filed under: Investing
Mobisante Launches Tablet Ultrasound System
REDMOND, Wash.–(BUSINESS WIRE)– Mobisante is pleased to announce the release of the MobiUS™TC1 tablet ultrasound system. Building upon the success and innovative features of the MobiUS SP1 smartphone ultrasound system, this system brings high-resolution point-of-care ultrasound imaging within reach of health care professionals everywhere, helping healthcare professionals practice better medicine and reduce costs. The system supports a quick look, triage, routine screening, and ultrasound-guided procedures to name a few. The MobiUS TC1 ultrasound system is an ideal choice for emergency departments, clinics, rural and community hospitals, disaster relief organizations, and the uniformed services.
Leveraging the power and ubiquity of cutting edge mobile computing technology, the MobiUS systems are available at a fraction of the cost of typical ultrasound systems. They utilize standards-based technology for easy implementation and shorter learning curves. The MobiUS TC1 is highly mobile and compact to fit into a broad range of uses and locations, and provides instant connectivity through Wi-Fi.
Quote from Sailesh Chutani, CEO and Co-Founder, “Devices like MobiUS TC1 enable more care to be provided outside of expensive settings like hospitals into settings that are less expensive, such as clinics and other locations where the patient needs immediate care. This is key to improving access while reducing costs.”
The system enables diagnosis and treatment in trauma (FAST exam, lung, cardiac screening), abdominal pain, AAA and other routine screening such as bladder assessment, OB/GYN assessments, triage, ultrasound-guided procedures and much more. The tablet also supports endocavity probes for gynecology or prostate imaging, in addition to the already wide array of probes that cover multiple clinical applications.
About Mobisante, Inc.
Mobisante, based in Redmond, Washington, aims to transform medical imaging by making safe, simple, non-invasive, and affordable ultrasound technology available to a broad range of clinicians. This allows them to move imaging closer to the point of patient care, which has been shown to improve clinical outcomes and efficiency in healthcare delivery. By leveraging the steadily increasing power and ubiquity of advanced, standards based mobile computing technology, Mobisante, www.mobisante.com, is able to provide simpler, more flexible and lower cost solutions that contrast to the expensive and complex products that previously limited broad access to point of care medical imaging.
Mobisante, Inc.
Director – Marketing, Mobisante
Lydia Zibin, 206-605-0600
lydia.zibin@mobisante.com<br …read more
Source: FULL ARTICLE at DailyFinance
Metabolix to Conduct a Webcast of Its Fourth Quarter and Fiscal Year 2012 Earnings Call
By Business Wirevia The Motley Fool
Filed under: Investing
Metabolix to Conduct a Webcast of Its Fourth Quarter and Fiscal Year 2012 Earnings Call
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Metabolix, Inc. (NAS: MBLX) , an innovation-driven bioscience company delivering sustainable solutions to the plastics, chemicals and energy industries, announced today that it will be releasing its fourth quarter and fiscal year 2012 financial results after the market close on Tuesday, March 26, 2013. The full text of the earnings release will also be available on the Company’s website at www.metabolix.com.
Richard Eno, the Company’s president and chief executive officer, Joseph Hill, chief financial officer, and Oliver Peoples, co-founder and chief scientific officer, will host a conference call on the same day at 4:30 p.m. (ET) to discuss the results of the fourth quarter and fiscal year ended December 31, 2012. The Company will also provide an update on the business and answer questions from the investment community.
A live webcast of the call with slides can be accessed through the “Investors” section of the Company’s website at www.metabolix.com. To participate in the call, dial toll-free (877) 709-8155 or (201) 689-8881 (international). Interested parties unable to participate in the live call may access an archived version of the webcast on the Company’s website. To listen to a telephonic replay of the conference call, dial toll-free (877) 660-6853 or (201) 612-7415 (international) and enter pass code 410216. The replay will be available beginning at 7:30 p.m. (ET) on Tuesday, March 26, 2013 and will last through 11:59 p.m. (ET) on April 9, 2013. In addition, the webcast will be archived on the Company’s website in the investor relations section.
About Metabolix
Metabolix, Inc. is an innovation-driven bioscience company delivering sustainable solutions to the plastics, chemicals and energy industries. Metabolix is developing and commercializing a family of high-performance biopolymers targeted to the markets for film and bag applications, performance additives and functional biodegradation. Metabolix’s biobased chemicals platform utilizes its novel “FAST” recovery process to enable the production of cost-effective, “drop-in” replacements for petroleum-based industrial chemicals. Metabolix is also developing a platform for co-producing plastics, chemicals and energy from crops. Metabolix has established an industry-leading intellectual property portfolio that, together with its knowledge of advanced industrial practice, provides a foundation for industry collaborations.
For more information, please visit www.metabolix.com.
(MBLX-E)